The AREA IN-CHF (Antiremodeling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure) study: Rational and design;Lo studio AREA IN-CHF (Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): Razionale e disegno

Italian Heart Journal, Supplement

Volumn 6, Issue 1, 2005, Pages

  Cacciatore, Giuseppe ^a   Boccanelli, Alessandro ^a   Mureddu, Gian Francesco ^a   Maggioni, Aldo Pietro ^b   Latini, Roberto ^c   Masson, Serge ^c   De Simone, Giovanni ^d  

^a SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^b ANMCO RESEARCH CENTER   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aldosterone receptor antagonist; Canrenone; Heart failure; Remodeling

Indexed keywords

ALDOSTERONE RECEPTOR; CANRENONE; EPLERENONE; MAGNESIUM; POTASSIUM; SODIUM;

ACUTE HEART INFARCTION; BLOOD VESSEL COMPLIANCE; DRUG EFFICACY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HOSPITALIZATION; HUMAN; PRESSORECEPTOR; REVIEW; SODIUM RETENTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; RECEPTORS, ALDOSTERONE; VENTRICULAR REMODELING;

EID: 29244468281     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82: 57-61.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
3. Pitt B, Remme WJ, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 384: 1309-21.
4. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.
5. Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49: 1659-66.
6. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-9.
7. Levine B, Kalman J, Mayer L, Fellet HM, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med 1990; 323: 236-41.
8. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 1983; 1: 1385-90.
9. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-95.
10. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
11. Massie BM. 15 years of heart-failure trials: what have we learned? Lancet 1998; 352 (Suppl 1): 29-33.
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
14. Pfeffer MA, Swedberg K, Granger CB, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Overall Trial. Lancet 2003; 362: 759-66.
15. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1350-5.
16. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1: 255-9.
17. Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
18. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLV Investigators. Circulation 1992; 86: 431-8.
19. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effect of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD Investigators. Circulation 1993; 88 (Part 1): 2277-83.
20. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
21. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29: 1060-6.
22. Lowes BD, Gill EA, Abraham W, et al. Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83: 1201-5.
23. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts. Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-20.
24. Yamamoto N, Yasue H, Mizuno Y, al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002; 39: 958-62.
25. Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role of cardiac fibrosis. Circulation 1999; 99: 2694-701.
26. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-7.
27. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action: mineralocorticoid receptors and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-82.
28. Bonvalet JP, Alfaidy N, Farman N, Lombes M. Aldosterone intracellular receptors in human heart. Eur Heart J 1995; 16: 92-7.
29. Sun Y, Cleutjens JP, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994; 28: 1423-32.
30. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an ACE inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259-65.
31. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-7.
32. Duprez DA, De Buyzere ML, Rietzchel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-6.
33. De Angelis N, Fiordaliso F, Latini R, et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 2002; 34: 1655-65.
34. Brown NJ, Agirbasli MA, Williams GA, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32: 965-71.
35. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82: 1730-6.
36. Swedberg K, Eneroth P, Kjekshus J, Snappin S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 1990; 66: 40D-44D.
37. Vaugham D, lamas G, Pfeffer M. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 529-32.
38. Benedict C, Johnstone D, Weiner D, et al. Relation of neurohumoral activation to clinical variables and degree of left ventricular dysfunction: a report from the registry of SOLVD. J Am Coll Cardiol 1994; 23: 1410-20.
39. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.
40. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, for the Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Results from the Valsartan Heart Failure Trial. Circulation 2003; 108: 1306-9.
41. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J 1995; 16 (Suppl N): 79-85.
42. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 2000; 102: 2700-6.
43. Cicoira M, Rossi A, Bonapace S, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004; 10: 403-11.
44. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci 1998; 95: 709-17.
45. McFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-4.
46. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993; 88: 1444-55.
47. Ochs HR, Greenblatt DJ, Bodem G, et al. Spironolactone. Am Heart J 1978; 96: 389-95.
48. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-8.
49. Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the aminoterminal propeptide of human type III procollagen. Clin Chem 1988; 34: 715-8.
50. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
51. de Simone G, Muiesan ML, Ganau A, et al. Reliability and limitations of echocardiographic measurements of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension. Reliability of M-Mode Echocardiographic Studies. J Hypertens 1999; 17 (Part 2): 1955-63.
52. Mureddu GF, Celentano A, Pasanisi F, et al. Pulmonary venous flow and mitral inflow velocity pattern in uncomplicated obesity: evidence for late diastolic dysfunction. Ital Heart J 2000; 1: 194-9.
53. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 56: 613-8.
54. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in arterial hypertension. J Am Coll Cardiol 1992; 19: 1550-8.
55. Konstam M, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 2003; 9: 350-3.
56. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations in myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-7.
57. Vasan RS, Evans JC, Benjamin EJ, et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 2004; 43: 957-62.
58. Modena MG, Aveta R Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001; 141: 41-6.
59. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228-33.
60. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-65.
61. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002; 40: 304-10.
62. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel adosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-72.
63. Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41: 574-81.
64. Antonopoulos GV, Lau J, Konstam MA, Udelson JE. Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? (abstr) Circulation 1999; 100: I-296.
65. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51.